Each year, EGFR exon 20 insertion mutations could rob ~60,000 patients of time, hope, and life[1][2][3][4][5][6][7][8][9]



Patients who have non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations (EGFRm ex20ins NSCLC) have a 75% increased risk of death (HR=1.75) compared to patients who have common EGFR-tyrosine kinase inhibitor (EGFR-TKI) sensitive mutations* in their tumours (median OS 16.2 vs 25.5 months, respectively).[10] The precious time that patients have left is often tainted by the negative emotional burden of the disease.**[11]



Patients with EGFRm ex20ins NSCLC generally experience limited outcomes with currently approved EGFR-TKIs.[1][2] In fact, response rates of these patients to EGFR-TKIs are approximately one third of those observed in patients who have EGFRm NSCLC without an ex20ins mutation.†,[8]



Due to the lack of effective targeted options, patients with EGFRm ex20ins NSCLC are most commonly prescribed chemotherapies as a first-line treatment, which are non-selective and have a wide range of side effects.[12][13][14][15]

don't miss the chance

Don’t miss the chance to treat EGFRm ex20ins NSCLC

Make EGFR exon 20 insertion mutations unmissable.

Discover more about EGFR exon 20 insertion mutations here:

What causes EGFR-TKI resistance?
Who do EGFR ex20ins mutations strike?
What impact do EGFR ex20ins mutations have on lives?

* EGFR exon 19 deletions and EGFR L858R point mutation.
** Qualitative interviews conducted with patients with NSCLC that had EGFR exon 20 mutations (n=10), 90% of whom had exon 20 insertion mutations. 100% of participants with EGFRm ex20ins NSCLC reported a psychological or emotional burden of their disease, and 60% described worries around treatment, the future, or finances.[11]
† Data taken from a meta-analysis of 61 studies, 12 of which reported overall response rate (ORR) in patients with EGFRm ex20ins NSCLC. Patient numbers not reported.[8] Mean ORR of patients with EGFRm NSCLC, without a detectable ex20ins mutation to EGFR-TKIs= 34.0% (13.9–84%). Mean ORR of patients with EGFRm ex20ins NSCLC to EGFR-TKIs= 11.9% (0.0–35.0%).[8]

EGFR, epidermal growth factor receptor; EGFRm, mutatedEGFR; EGFR-TKI, EGFR-tyrosine kinase inhibitor; ex20ins, exon 20 insertion; HR, hazard ratio; mOS, median overall survival; NSCLC, non-small cell lung cancer; ORR, overall response rate.



Yasuda H et al. Sci Transl Med 2013; 5(216): 216ra177.
Vyse S et al. Signal Transduct Target Ther 2019; 4: 5.
Data on file_Medscape activity and JMC content_Annual global prevalence of EGFR ex20ins, 2020.
Bray F et al. CA Cancer J Clin 2018; 68(6): 394–424.
Zappa C et al. Transl Lung Cancer Res 2016; 5(3): 288–300.
Zhang Y et al. Oncotarget 2016; 7(48): 78985–78993.
Li Y et al. PLoS ONE 2019; 14(1): e0209709.
Crossland V et al. JNCCN 2019; 17(3.5): HSR19-082.
Masood A et al. Semin Oncol 2019; 46(3): 271–283.
Girard N et al. Abstract presented at the IASLC 2020 World Conference on Lung Cancer. 28–31 January 2021. Singapore, worldwide virtual event. MA04.07.
Bell J et al. JTO 2018; 13(10): S991–S992.
Dersarkissian M et al. Poster presented at the International Association for the Study of Lung Cancer (IASLC) 2019 World Conference on Lung Cancer. September 7–10 2019. Barcelona, Spain. P2.01–103.
Dong J et al. Front Pharmacol 2019; 10: 230.
Huang C et al. Biomedicine 2017; 7(4): 12–23.
Rosell et al. Lancet Oncol 2012; 13(3): 239–246.